Your browser doesn't support javascript.
loading
Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.
Moffett, H F; Coon, M E; Radtke, S; Stephan, S B; McKnight, L; Lambert, A; Stoddard, B L; Kiem, H P; Stephan, M T.
Afiliación
  • Moffett HF; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Coon ME; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Radtke S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Stephan SB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • McKnight L; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Lambert A; Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Stoddard BL; Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Kiem HP; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
  • Stephan MT; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, 98109, USA.
Nat Commun ; 8(1): 389, 2017 08 30.
Article en En | MEDLINE | ID: mdl-28855514
ABSTRACT
Therapies based on immune cells have been applied for diseases ranging from cancer to diabetes. However, the viral and electroporation methods used to create cytoreagents are complex and expensive. Consequently, we develop targeted mRNA nanocarriers that are simply mixed with cells to reprogram them via transient expression. Here, we describe three examples to establish that the approach is simple and generalizable. First, we demonstrate that nanocarriers delivering mRNA encoding a genome-editing agent can efficiently knock-out selected genes in anti-cancer T-cells. Second, we imprint a long-lived phenotype exhibiting improved antitumor activities into T-cells by transfecting them with mRNAs that encode a key transcription factor of memory formation. Third, we show how mRNA nanocarriers can program hematopoietic stem cells with improved self-renewal properties. The simplicity of the approach contrasts with the complex protocols currently used to program therapeutic cells, so our methods will likely facilitate manufacturing of cytoreagents.Current widely used viral and electroporation methods for creating therapeutic cell-based products are complex and expensive. Here, the authors develop targeted mRNA nanocarriers that can transiently program gene expression by simply mixing them with cells, to improve their therapeutic potential.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: ARN Mensajero / Técnicas de Reprogramación Celular Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2017 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: ARN Mensajero / Técnicas de Reprogramación Celular Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2017 Tipo del documento: Article